So far this year Allogene has barreled out of left field with a pair of the most experienced CAR-T execs in the industry steering the new business to a record-setting (for now) IPO. And they’re headed straight into their first update on data for what an off-the-shelf CAR-T can do for patients suffering from acute lymphoblastic leukemia — with what they believe is a manageable safety profile.
Still tinkering with what they envision is just the right kind of edited CAR-T for the work, their UCART19 program — picked up from Pfizer and partnered with Cellectis — produced some promising proof-of-concept results on the first 21 patient results pooled from two small studies. Fourteen out of 17 pre-treated with a standard flu/cy lymphodepletion regimen plus an immunosuppressing therapy achieved a complete response with significant cell expansion.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.Free Subscription